A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE010 (ESP) · Dr. Silva
consented 2022-11-09
AEs
4
Serious
0
Dropout signal
–
Adverse events
mild
assessed
Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-11-29 (study day 2); relationship: N
mild
assessed
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-01-03 (study day 37); relationship: N
severe
assessed
Grade 3 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-01-22 (study day 56); relationship: not assessed
mild
assessed
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-01-31 (study day 65); relationship: not assessed
Data queries
No data queries.